No 01 2026

Sobi has announced positive topline results from the pivotal Phase 3 REDUCE 2 study evaluating pozdeutinurad (AR882), an investigational next-generation once-daily oral selective URAT1 inhibitor, in adults with gout including those with uncontrolled gout (also referred to as progressive gout) and inadequately controlled by existing therapies.

The company has announced an investment led by HealthCap, and conjunction with this capital infusion, Neobiomics strengthens its board with the appointment of a new director, Mårten Steen, Managing Partner at HealthCap. 

Industry, academic, and public stakeholders will join forces in a new council aimed at accelerating the region's life science development.

Oncopeptides' clinical trial application for the "Window-of-Opportunity" (WoO) study in glioblastoma has been formally approved in Norway.

The orphan drug designation has been granted for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing’s disease.

The company has now received GMP (Good Manufacturing Practice) certification as well as manufacturing authorization from the Swedish Medical Products Agency for the production of biological investigational medicinal products for human use.

Herantis Pharma has announced a collaboration with Indivi, a Basel-based TechBio company focused on advancing precision medicine in neuroscience drug development, to integrate Indivi's digital biomarker platform into Herantis' upcoming Phase 2 proof-of-concept study of HER-096 in people living with Parkinson's disease.